TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03635528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: EMO-116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: EMO-116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: EMO-116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: EMO-116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: EMO-116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: EMO-116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: EMO-116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: EMO-116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: EMO-116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: EMO-116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: EMO-116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 2
Description: EMO-116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: EMO-118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: EMO-118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: EMO-118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: EMO-118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: EMO-118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: EMO-118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: EMO-118
Study: NCT01963871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Twice weekly one hour sessions of Hatha Yoga for 12 weeks
Study: NCT01776086

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neurological testing
Study: NCT02247388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Alcohol Screening
Description: iPad based automated alcohol screening

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Negotiated Interview
Description: iPad based automated brief negotiated interview (BNI)
Study: NCT03659630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyCompass
Description: Self-help tools to change behaviours in various different domains including sleep deprivation, anxiety and depression.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparison group
Description: An email containing a brief text on general tips regarding mental health was sent out once a week.
Study: NCT03863353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.
Study: NCT01330082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjunctive Photodynamic Therapy
Description: using Light-emitting diod(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark) in the presence of toluidine blue O (TBO)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light-emitting diod Irradiation
Description: 625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: applying Photosensitizer
Description: toluidine blue O is applied at the bottom of each periodontal pocket
Study: NCT02108301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus-cyclosporine A
Description: conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients
Study: NCT03171090

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sphenopalatine block with local anesthetic
Description: bilateral ultrasonic guided sphenopalatine ganglion block using local anesthetic after induction of general anesthesia in maxilofacial cancer surgeries
Study: NCT03635528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: EMO-118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: EMO-118
Study: NCT03171090

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sphenopalatine block with saline
Description: bilateral ultrasonic guided sphenopalatine ganglion block using saline after induction of general anesthesia in maxilofacial cancer surgeries
Study: NCT00167700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counselling and placebo
Description: Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Placebo capsules.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counselling and probiotics
Description: Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Probiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Study: NCT03635528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: EMO-118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: EMO-118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: EMO-118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: EMO-118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 3
Description: EMO-118
Study: NCT00167700

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotics
Study: NCT00595361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol
Description: salmeterol 50 micrograms twice daily for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmeterol
Description: salmeterol 50 micrograms twice daily for 2 weeks
Study: NCT05647187

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum Interleukin 17 levels
Description: Serum Interleukin 17 levels will be measured pre and post treatment by NB-UVB by performing an enzyme-linked immune sorbent assay (ELISA)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB
Description: patients will be exposed to narrow band UVB twice weekly for three months
Study: NCT02779985

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycium Barbarum mixed meal
Description: This mixed meal contains 25 grams of dried Lycium Barbarum (Goji berry, Wolfberry)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control mixed meal
Description: This mixed meal does not contain Lycium Barbarum, but is matched for energy and macronutrient content
Study: NCT04079790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Tablets containing gepotidacin mesylate with a unit dose of 750 mg will be administered orally with 240 milliliter (mL) of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gepotidacin
Description: Tablets containing gepotidacin mesylate with a unit dose of 750 mg will be administered orally with 240 milliliter (mL) of water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets containing unit dose of placebo matching of gepotidacin will be administered orally with 240 mL of water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets containing unit dose of placebo matching of gepotidacin will be administered orally with 240 mL of water.
Study: NCT03434288

Intervention type: OTHER
Intervention: Bone sampling
Description: Bone biopsy in Diabetic patients with foot osteomyelitis
Study: NCT04351620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Tolerability study of HCQ 1200 mg administered daily in divided doses for a duration of 5-10 days
Study: NCT02618746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital based Rehabilitation
Study: NCT02136693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psyllium fiber
Description: 3.5 g /day of pure Psyllium fiber for 180 days after STARR

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3.5 g /day of inert compound for 180 days after STARR
Study: NCT01482559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine hydrochloride
Description: Active drug substance 1.5 mg in 1 mL IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose 5%
Description: IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
Study: NCT02064556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg
Description: Amlodipine 10mg 1T, PO, QD for 9days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg/Candesartan 32mg
Description: Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days
Study: NCT02745106

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency pulmonary artery denervation
Description: Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation catheter
Description: 4MM RF CONDUCTR (MULTI-CURVE) SERIES ABLATION CATHETER Standart procedure for radiofrequency ablation: Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Swan-Ganz catheter for right heart catheterization
Description: Standart procedure of right catheterization:~* punction of right jugular vein with Seldinger technique, introducer placement~* insertion of Swan-Ganz catheter via introducer in jugular vein under fluoroscopic control and wave form of monitor's curve.~* positioning of swan-ganz catheter in pulmonary artery~* direct central hemodynamics measurements: systolic/diastolic/mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac output (thermodilution technique)~* calculating of indirect parameters (pulmonary vascular resistance)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Swan-Ganz catheter for right heart catheterization
Description: Standart procedure of right catheterization:~* punction of right jugular vein with Seldinger technique, introducer placement~* insertion of Swan-Ganz catheter via introducer in jugular vein under fluoroscopic control and wave form of monitor's curve.~* positioning of swan-ganz catheter in pulmonary artery~* direct central hemodynamics measurements: systolic/diastolic/mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac output (thermodilution technique)~* calculating of indirect parameters (pulmonary vascular resistance)
Study: NCT06523179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quantify the impact of genetic risk factors
Description: the impact of genetic risk factors for the development of NAFLD-HCC and their interaction with acquired risk factors, on the incidence of the disease in a prospective cohort of patients at risk, through a score capable of predicting NAFLD-HCC and selecting patients for whom screening is cost-effective.
Study: NCT01549158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: torasemide-PR
Description: Single oral dose of torasemide PR 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide-IR
Description: Single oral dose of furosemide IR 40 mg
Study: NCT03635528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 4
Description: RMY-100
Study: NCT01549158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: torasemide-IR
Description: Single oral dose of torasemide IR 10 mg
Study: NCT03546465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropeginterferon alfa-2b
Description: 6 subjects in each cohort will receive a single dose by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropeginterferon alfa-2b
Description: 6 subjects in each cohort will receive a single dose by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropeginterferon alfa-2b
Description: 6 subjects in each cohort will receive a single dose by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropeginterferon alfa-2b
Description: 6 subjects in each cohort will receive a single dose by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropeginterferon alfa-2b
Description: 6 subjects in each cohort will receive a single dose by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropeginterferon alfa-2b
Description: 6 subjects in each cohort will receive a single dose by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropeginterferon alfa-2b
Description: 6 subjects in each cohort will receive a single dose by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropeginterferon alfa-2b
Description: 6 subjects in each cohort will receive a single dose by subcutaneous injection
Study: NCT01923519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchofiberscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchofiberscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchofiberscopy
Study: NCT01704365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose RSV-F Vaccine with Adjuvant
Description: 0.5mL IM Injection
Study: NCT03635528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 4
Description: RMY-100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 4
Description: RMY-100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 4
Description: RMY-100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 4
Description: RMY-100
Study: NCT01704365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose RSV-F Vaccine with Adjuvant
Description: 0.5mL IM Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose RSV-F Vaccine without Adjuvant
Description: 0.5ml IM Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose RSV-F Vaccine without Adjuvant
Description: 0.5ml IM Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose RSV-F Vaccine with Adjuvant
Description: 0.5mL IM Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose RSV-F Vaccine with Adjuvant
Description: 0.5mL IM Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose RSV-F Vaccine without Adjuvant
Description: 0.5mL IM Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose RSV-F Vaccine without Adjuvant
Description: 0.5mL IM Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing]
Description: 0.5mL IM Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5mL IM Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5mL IM Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5mL IM Injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5mL IM Injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5mL IM Injection
Study: NCT04581915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triazavirin (Riamilovir)
Description: Capsule - 250mg 8 hourly po

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT00566488

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymus/Parathyroid Transplantation
Description: Thymus tissue, thymus donor, mother of thymus donor, \& parental parathyroid donor screened for transplant safety. Depending on T cell phenotype \& function, subjects were given 1 of 2 immunosuppression regimes. All received rabbit anti thymocyte globulin pretransplantation. Others also received cyclosporine pre \& post-transplantation. The thymus dose was over 0.2 grams/kg recipient weight. Thymus transplant occurred in operating room; thymic slices were placed in quadriceps. Parathyroid harvest was done under general anesthesia. One parathyroid gland was minced and placed in quadriceps muscle. There was no dose in mg. An open biopsy of thymus allograft was done 2-3 months post-transplant. Biopsy tissue was examined by immunohistochemistry to evaluate for thymopoiesis \& graft rejection.
Study: NCT03879031

Intervention type: DIAGNOSTIC_TEST
Intervention: Cluster of Clinical tests to measure lumbar stability
Description: All subjects will be submitted to a cluster of clinical test before the starting of the first session, and at the ending of the last session of the physical therapy program. This cluster will include:~* Aberrant Movements (AM) Test,~* Active Straight Leg Raise Test (ASLR) Test,~* Supine Bridge Test (SuBT),~* Right Side Bridge Test (RBT),~* Left Side Bridge Test (LBT),~* Prone Bridge Test (PrBT),~* Passive Lumbar Extension (PLE) Test,~* Prone Instability Test (PIT).
Study: NCT05233813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Body and Mind
Description: The intervention group attended three 45-min group exercise lessons per week and wore a Fitbit activity tracker during the weekdays for 12 weeks combined with weekly feedback and personalized activity goals.
Study: NCT01664091

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: post-mastectomy radiation therapy (PMRT)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tissue expander (TE)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acellular dermal matrix (ADM)
Study: NCT00748202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C1-Esterase Inhibitor
Description: 1000 I.E.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C1-Esterase Inhibitor
Description: 1000 I.E.
Study: NCT04556747

Intervention type: OTHER
Group type: OTHER
Intervention: VR - Distraction
Description: Participants will be instructed to use any application.

Intervention type: OTHER
Group type: OTHER
Intervention: VR - Biofeedback
Description: Participants will be instructed to use the Mindful Aurora application.
Study: NCT01105052

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help CBT-I
Description: Comparison between Bibliotherapy with and without support to a wait-list control group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help CBT-I
Description: Comparison between Bibliotherapy with and without support to a wait-list control group
Study: NCT02559167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: The investigators will carry out a double-blind, randomized, controlled trial comparing the effects of 92 days of 400 (only for the first 2 Days starting on the Day 2 of the study) or 800 mg CBD (subjects who report side effects with the 800mg dose will be administered the CBD 400 mg dose for the remainder of the trial) vs. placebo administration on cocaine craving and relapse in 110 cocaine-dependent subjects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabidiol
Description: The investigators will carry out a double-blind, randomized, controlled trial comparing the effects of 92 days of 400 (only for the first 2 Days starting on the Day 2 of the study) or 800 mg CBD (subjects who report side effects with the 800mg dose will be administered the CBD 400 mg dose for the remainder of the trial) vs. placebo administration on cocaine craving and relapse in 110 cocaine-dependent subjects.
Study: NCT00908934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9056 formulation Phase III 50 mg (T)
Description: Given as 50 mg tablet (T)
Study: NCT03635528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 4
Description: RMY-100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 4
Description: RMY-100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 4
Description: RMY-100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 4
Description: RMY-100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 4
Description: RMY-100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 5
Description: Biofinity multifocal D Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 5
Description: Biofinity multifocal D Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 5
Description: Biofinity multifocal D Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 5
Description: Biofinity multifocal D Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lens 5
Description: Biofinity multifocal D Lens
Study: NCT00908934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9056 formulation Phase IIb 50 mg (R)
Description: Given as 50 mg tablet (R)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9056 formulation Phase III 200 mg (T)
Description: Given as 400 mg (2 x 200 mg tablet (T))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9056 formulation Phase IIb 200mg (R)
Description: Given as 400 mg (2 x 200 mg tablet (R))
Study: NCT02111200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Benzoate
Description: Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.